Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis.
cUTI
ceftolozane/tazobactam
neonates
pyelonephritis
young infants
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
12 Sep 2023
12 Sep 2023
Historique:
medline:
12
9
2023
pubmed:
12
9
2023
entrez:
12
9
2023
Statut:
aheadofprint
Résumé
Ceftolozane/tazobactam is approved for the treatment of patients from birth to <18 y old with complicated urinary tract infections (cUTI). This post hoc analysis evaluated the safety, efficacy, and pharmacokinetics (PK) of ceftolozane/tazobactam compared with meropenem in neonates and young infants. NCT03230838 was a phase 2, randomized, active comparator-controlled, double-blind study of patients from birth to <18 y of age with cUTI, including pyelonephritis, given ceftolozane/tazobactam or meropenem in a 3:1 ratio. This subset analysis included only neonates and young infants < 3 mo of age. The microbiologic modified intent-to-treat population (mMITT) included 20 patients (ceftolozane/tazobactam,
Identifiants
pubmed: 37698430
doi: 10.1128/spectrum.01800-23
pmc: PMC10581202
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0180023Références
Pharmacol Res. 2016 Jun;108:80-87
pubmed: 27142783
Front Cell Infect Microbiol. 2021 Jul 12;11:694093
pubmed: 34322398
Pediatr Infect Dis J. 2023 Jul 1;42(7):557-563
pubmed: 37000942
Iran J Kidney Dis. 2012 May;6(3):166-72
pubmed: 22555478
Pediatr Infect Dis J. 2023 Apr 1;42(4):292-298
pubmed: 36689671
J Infect. 2016 Dec;73(6):547-557
pubmed: 27475789
Am J Emerg Med. 2017 Jan;35(1):36-38
pubmed: 27742519
Clin Pharmacokinet. 2014 Jul;53(7):581-610
pubmed: 24871768
Am J Perinatol. 2014 Oct;31(9):811-21
pubmed: 24347262
J Pediatr. 2022 Jan;240:66-71.e4
pubmed: 34481808
J Am Soc Nephrol. 2009 Mar;20(3):629-37
pubmed: 19158356
J Pediatric Infect Dis Soc. 2017 Nov 24;6(4):352-359
pubmed: 27856730
Clin Infect Dis. 2016 Jul 15;63(2):234-41
pubmed: 27098166
Curr Clin Pharmacol. 2017;12(1):18-25
pubmed: 28322168
Pediatr Int. 2016 Jun;58(6):467-71
pubmed: 26513232
Pediatr Clin North Am. 2012 Oct;59(5):1205-20
pubmed: 23036252
Pediatr Infect Dis J. 2018 Nov;37(11):1130-1136
pubmed: 30153232
J Clin Pharmacol. 2021 Feb;61(2):254-268
pubmed: 32949031
JAMA. 2012 May 9;307(18):1914-5
pubmed: 22570457
Pediatr Nephrol. 2009 Feb;24(2):309-12
pubmed: 18830717
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30962340
J Pediatric Infect Dis Soc. 2014 Dec;3(4):320-8
pubmed: 26625452
Pediatr Infect Dis J. 2008 Apr;27(4):302-8
pubmed: 18316994
Br J Clin Pharmacol. 2015 Mar;79(3):370-8
pubmed: 25041601
Am J Perinatol. 2021 Jul;38(8):804-809
pubmed: 31910460
Pediatr Infect Dis J. 2023 Feb 1;42(2):106-109
pubmed: 36638394
Pediatr Infect Dis J. 2010 Feb;29(2):139-44
pubmed: 20135833